Autobahn Therapeutics wanted to take advantage of the neuropsychiatric benefits observed with thyroid hormone therapy without systemic side effects, so the company used its proprietary technology for oral drugs that can cross the blood-brain barrier to develop a thyromimetic as an adjunctive treatment for depression. Now, with $100m in series C venture capital in hand, Autobahn plans to initiate Phase II clinical trials later this year for lead drug candidate ABX-002.
Autobahn Speeds Lead Drug Into Phase II With $100m In Fresh Cash
Second Candidate Headed For Phase I In 2025
Autobahn raised $100m in series C venture capital to take its oral, brain-penetrant thyromimetic ABX-002 into Phase II studies in major depressive disorder and bipolar disorder depression.
